Next Article in Journal
Circular RNA as a Novel Biomarker for Diagnosis and Prognosis and Potential Therapeutic Targets in Multiple Myeloma
Previous Article in Journal
Energy Sources for Exosome Communication in a Cancer Microenvironment
Article

Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients

1
Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
2
Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
3
Department of Medical Ethics, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
4
Institute of Health Information and Statistics of the Czech Republic, 128 01 Prague, Czech Republic
5
Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
6
Department of Pharmacy, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
7
Department of Surgical Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
8
Department of Surgical Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
9
Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
10
Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
11
Department of Pharmacy, University Hospital Brno, 625 00 Brno, Czech Republic
12
Department of Pharmacology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
13
Clinical Trial Unit, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic
*
Author to whom correspondence should be addressed.
Academic Editors: Sung Eun Kim, Arun Dharmarajan and Paula Guedes De Pinho
Cancers 2022, 14(7), 1699; https://doi.org/10.3390/cancers14071699
Received: 6 February 2022 / Revised: 17 March 2022 / Accepted: 24 March 2022 / Published: 27 March 2022
(This article belongs to the Topic Cancer Cell Metabolism)
Hypolipidemic drugs are among the most frequently prescribed medications in the Western world. Since many studies have indicated their role in carcinogenesis, this work aimed to investigate their association with the occurrence of a second primary malignancy in colorectal cancer survivors. The overall incidence of a second neoplasm was not linked to hypolipidemic medication; however, a subgroup analysis revealed a lower incidence of secondary neoplasia in statin users. When stratified by cancer types, a significant increase in gastric and bladder cancer was detected among colorectal cancer patients using hypolipidemic drugs. Survival outcomes in patients with early-stage colorectal carcinoma who suffered second cancer were significantly worse if treated with hypolipidemic drugs. Although our results do not provide evidence for a causative relationship between hypolipidemic medication and carcinogenesis, these correlations might steer the direction of tertiary prevention care towards specific risk factors shared between cardiovascular diseases and cancer.
An increasing number of studies has brought evidence of the protective role of statin use against different types of cancer. However, data on their association with second primary malignancies (SPMs) are lacking. The purpose of this study was to determine the role of hypolipidemic treatment in the prevention of second primary cancer in colorectal cancer (CRC) survivors. We conducted a retrospective single-institution study of 1401 patients with newly diagnosed colorectal cancer from January 2003 to December 2016, with follow-up until December 2020. An SPM was detected in 301 patients (21%), and the incidence was significantly lower in patients with statin medication. However, stratification by cancer types revealed an increased incidence of bladder and gastric cancer in hypolipidemic users. A Kaplan−Meier analysis of early-stage CRC survivors with an SPM showed a significant survival benefit in patients without a history of hypolipidemic treatment. Despite the protective role of statins on overall second cancer incidence, these data indicate that CRC survivors treated with hypolipidemic drugs should be screened more cautiously for SPMs, especially for gastric and bladder cancer. View Full-Text
Keywords: hypolipidemic agents; statins; second primary malignancies; second primary cancers; multiple primary neoplasms; colorectal cancer; cancer survivors hypolipidemic agents; statins; second primary malignancies; second primary cancers; multiple primary neoplasms; colorectal cancer; cancer survivors
Show Figures

Figure 1

MDPI and ACS Style

Halámková, J.; Bohovicová, L.; Pehalová, L.; Goněc, R.; Staněk, T.; Kazda, T.; Mouková, L.; Krákorová, D.A.; Kozáková, Š.; Svoboda, M.; Demlová, R.; Kiss, I. Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients. Cancers 2022, 14, 1699. https://doi.org/10.3390/cancers14071699

AMA Style

Halámková J, Bohovicová L, Pehalová L, Goněc R, Staněk T, Kazda T, Mouková L, Krákorová DA, Kozáková Š, Svoboda M, Demlová R, Kiss I. Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients. Cancers. 2022; 14(7):1699. https://doi.org/10.3390/cancers14071699

Chicago/Turabian Style

Halámková, Jana, Lucia Bohovicová, Lucie Pehalová, Roman Goněc, Teodor Staněk, Tomáš Kazda, Lucie Mouková, Dagmar A. Krákorová, Šárka Kozáková, Marek Svoboda, Regina Demlová, and Igor Kiss. 2022. "Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients" Cancers 14, no. 7: 1699. https://doi.org/10.3390/cancers14071699

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop